M
Matteo Brighenti
Researcher at Concordia University Wisconsin
Publications - 36
Citations - 1246
Matteo Brighenti is an academic researcher from Concordia University Wisconsin. The author has contributed to research in topics: Lung cancer & Chemotherapy. The author has an hindex of 11, co-authored 32 publications receiving 808 citations.
Papers
More filters
Journal ArticleDOI
COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study.
Marina Chiara Garassino,Jennifer G. Whisenant,Li-Ching Huang,Annalisa Trama,Valter Torri,Francesco Agustoni,Javier Baena,Giuseppe Luigi Banna,Rossana Berardi,Anna Cecilia Bettini,Emilio Bria,Matteo Brighenti,Jacques Cadranel,Alessandro De Toma,Claudio Chini,Alessio Cortellini,Enriqueta Felip,Giovanna Finocchiaro,Pilar Garrido,Carlo Genova,Raffaele Giusti,Vanesa Gregorc,Francesco Grossi,Federica Grosso,Salvatore Intagliata,Nicla La Verde,Stephen V. Liu,Julien Mazieres,Edoardo Mercadante,Olivier Michielin,Gabriele Minuti,Denis Moro-Sibilot,Giulia Pasello,Antonio Passaro,Vieri Scotti,Piergiorgio Solli,Elisa Stroppa,Marcello Tiseo,Giuseppe Viscardi,Luca Voltolini,Yi-Long Wu,Silvia Zai,Vera Pancaldi,Anne Marie C. Dingemans,Jan P. van Meerbeeck,Fabrice Barlesi,Heather A. Wakelee,Solange Peters,Leora Horn +48 more
TL;DR: With an ongoing global pandemic of COVID-19, the data suggest high mortality and low admission to intensive care in patients with thoracic cancer and whether mortality could be reduced with treatment in intensive care remains to be determined.
Journal ArticleDOI
Association of Steroids Use with Survival in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
Fausto Petrelli,Diego Signorelli,Michele Ghidini,Antonio Ghidini,Elio Gregory Pizzutilo,Lorenzo Ruggieri,Mary Cabiddu,Karen Borgonovo,Giuseppina Dognini,Matteo Brighenti,Alessandro De Toma,Erika Rijavec,Marina Chiara Garassino,Francesco Grossi,Gianluca Tomasello +14 more
TL;DR: A systematic review and meta-analysis of published studies to evaluate the correlation between steroids use, overall survival (OS), and progression-free survival (PFS) in cancer patients treated with ICIs was performed in this paper.
Journal ArticleDOI
Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial
Marcello Tiseo,Luca Boni,Francesca Ambrosio,Andrea Camerini,Editta Baldini,Saverio Cinieri,Matteo Brighenti,F. Zanelli,Efisio Defraia,Rita Chiari,Claudio Dazzi,Carmelo Tibaldi,Gianni Michele Turolla,Vito D'Alessandro,Nicoletta Zilembo,Anna Rita Trolese,Francesco Grossi,Ferdinando Riccardi,Andrea Ardizzoni +18 more
TL;DR: The addition of bevacizumab to cisplatin and etoposide in the first-line treatment of ED-SCLC had an acceptable toxicity profile and led to a statistically significant improvement in progression-free survival, which, however, did not translate into a statisticallysignificant increase in OS.
Journal ArticleDOI
Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study
Sandro Barni,Roberto Labianca,Giancarlo Agnelli,Erminio Bonizzoni,Melina Verso,Mario Mandalà,Matteo Brighenti,Fausto Petrelli,Carlo Bianchini,Tania Perrone,Giampietro Gasparini +10 more
TL;DR: This retrospective analysis confirms that patients undergoing chemotherapy including gemcitabine, platinum analogues or their combination are at higher risk of TEs and suggests that outpatients receiving chemotherapy regimens including these agents might achieve an increased benefit from thromboprophylaxis with nadroparin.
Journal ArticleDOI
Immune-related Adverse Events and Survival in Solid Tumors Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
Fausto Petrelli,Giulia Grizzi,Michele Ghidini,Antonio Ghidini,Margherita Ratti,Stefano Panni,Mary Cabiddu,Mara Ghilardi,Karen Borgonovo,Maria Chiara Parati,Gianluca Tomasello,Sandro Barni,Alfredo Berruti,Matteo Brighenti +13 more
TL;DR: In patients treated with ICIs, irAEs predict survival and response, and although this correlation cannot be fully explained, it may be related to the strongest T-cell activation.